Product Information
XIGDUO XR 2.5 MG-1,000 MG TAB is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $9.6082 per EA under NDC 00310622560. Its NADAC has been published 390 times since Apr 17, 2019.
FDA first approved this application on Oct 29, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5; 1000 mg/1; mg/1
Manufacturer
AstraZeneca Pharmaceuticals LPNDC
00310622560
Classification
Brand
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA205649FDA Approved
10/29/2014
TE Code
AB
On Market Since
10/29/2014
Pharmacological Classes
Price Statistics
The NADAC for XIGDUO XR 2.5 MG-1,000 MG TAB has been published 390 times since Apr 17, 2019, and over the history we have for it it has risen 21.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.6082 per EA |
|---|---|
| All-time high | $9.6103 (Oct 15, 2025) |
| All-time low | $7.9172 (Apr 17, 2019) |
| 52-week high | $9.6103 |
| 52-week low | $9.5896 |
| Median price | $8.9014 |
| Average price | $8.8827 |
| Largest weekly change | +3.0% (Jan 12, 2022) |
| Weeks tracked | 390 |
| Tracking since | Apr 17, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the dapagliflozin and metformin hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AstraZeneca Pharmaceuticals LP manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
dapagliflozin and metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XIGDUO XR 2.5 MG-1,000 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for XIGDUO XR 2.5 MG-1,000 MG TAB, manufactured by AstraZeneca Pharmaceuticals LP, is $9.6082 per EA (NDC 00310622560), effective Sep 30, 2026.
How has the price of XIGDUO XR 2.5 MG-1,000 MG TAB changed over time?
Over the history we have for it, the NADAC for XIGDUO XR 2.5 MG-1,000 MG TAB has risen 21.4%. It has been tracked across 390 weekly CMS publications since Apr 17, 2019.
What are the highest and lowest recorded NADAC prices for XIGDUO XR 2.5 MG-1,000 MG TAB?
Since Apr 17, 2019, the NADAC for XIGDUO XR 2.5 MG-1,000 MG TAB has ranged from a low of $7.9172 (Apr 17, 2019) to a high of $9.6103 (Oct 15, 2025), with a median of $8.9014 per EA.
Are there cheaper alternatives to XIGDUO XR 2.5 MG-1,000 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of XIGDUO XR 2.5 MG-1,000 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XIGDUO XR 2.5 MG-1,000 MG TAB?
XIGDUO XR 2.5 MG-1,000 MG TAB (NDC 00310622560) is labeled by AstraZeneca Pharmaceuticals LP, and CMS classifies it as a brand product.